|
|
|
|
||
latest Vidaza trial add - drug cocktail after SC transplant, CML phase 2Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
This study is currently recruiting participants.
Verified by M.D. Anderson Cancer Center, December 2008
Purpose
Objectives:
Drug Information available for:
Methotrexate
Fludarabine
Fludarabine monophosphate
Tacrolimus
Azacitidine
Tacrolimus anhydrous
Busulfan
Study Type:
Interventional
Study Design:
Treatment, Open Label, Single Group Assignment, Efficacy Study
Official Title:
Azacitidine Maintenance Therapy After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)
Further study details as provided by M.D. Anderson Cancer Center:
Primary Outcome Measures:
Estimated Enrollment:
32
Study Start Date:
December 2008
Estimated Primary Completion Date:
December 2013 (Final data collection date for primary outcome measure)
Show Detailed Description
Eligibility
Ages Eligible for Study:
18 Years to 75 Years
Genders Eligible for Study:
Both
Accepts Healthy Volunteers:
No
Criteria
Inclusion Criteria:
Exclusion Criteria:
|
return to message board, top of board |